Zami Aberman is being welcomed for a second year to the Board of Directors of the Washington, DC-based Alliance for Regenerative Medicine (ARM). Aberman is chairman and CEO of Pluristem Therapeutics, Inc., a company that has been a member of ARM for four years and has actively supported the organization’s goals.
Zami Aberman Re-elected to Board of ARM
1 min read Premium comments
Aberman said in the October 13, 2016 news release, “I am honored to be re-elected to the Board of ARM. Over the past year, Pluristem has made a meaningful contribution to this very important organization, which advances the regenerative medicine industry for the benefit of patients and healthcare systems around the globe.”
Asked how he hopes to affect change, Aberman told OTW, “I hope to work with my colleagues at ARM to generate global interest in the regenerative space and to develop an international network of interested parties.”
As for his goals over the next several months, he commented, “I want to develop a better understanding of the different reimbursement models for cell therapy across the world; develop a global approach to advanced regulatory pathways; and develop effective communication about the progress of the cell therapy sector.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.